We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Roche Recognizes med fusion as a Molecular Center of Excellence

By LabMedica International staff writers
Posted on 06 Jun 2012
Print article
Roche Diagnostics (Roche; Basel, Switzerland), a biotech company focused on research-based healthcare, has formed an alliance with med fusion LLC (Lewisville, Texas, USA), an integrated laboratory and clinical trials service organization, designating the company as a Roche Molecular Center of Excellence (MCOE) for the next five years.

Established in 2002, Roche's MCOE program allows noncompeting regional laboratories across the United States to collaborate and capitalize on molecular testing instruments in order to advance test methodologies and technology.

As a nationally recognized Roche MCOE, med fusion's molecular diagnostics laboratory will offer healthcare professionals and patients some of the latest and most advanced molecular technologies, including Roche's cobas 4800 BRAF V600 Mutation Test, a companion diagnostic that identifies patients who are eligible for treatment with the ZELBORAF (vemurafenib) drug for inoperable or metastatic melanoma, a deadly form of skin cancer.

"Roche is very pleased to welcome med fusion into the Molecular Center of Excellence alliance," said Whitney Green, senior vice president, molecular diagnostics, Roche Diagnostics Corporation. "We value their expertise and look forward to working together in implementing molecular technologies in the advancement of personalized medicine."

med fusion is one of 35 labs in the United States and 3 in Texas that have received this accolade. According to Dr. Thomas Lohmann, chief medical officer, med fusion, the partnership with Roche will help the company provide healthcare professionals and patients with improved diagnostic services.

"This relationship with Roche will help keep med fusion on the leading edge of technology and help ensure that we are supporting physicians and patients with the most advanced molecular technologies," added Dr. Lohmann.

Roche is an industry leader in pharmaceuticals and diagnostics, providing a broad range of products and services for the early detection, prevention, diagnosis, and treatment of diseases.



Related Links:

Roche Diagnostics

med fusion

New
Gold Member
C-Reactive Protein Reagent
CRP Ultra Wide Range Reagent Kit
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
New
Alpha-1-Antitrypsin ELISA
IDK alpha-1-Antitrypsin ELISA

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.